Search the Newsreel

Hyperion DeFi Redeploys 1M HYPE Tokens for HIP-3 and HIP-4 Markets

Needham & Company LLC Raises Definium Therapeutics (NASDAQ:DFTX) Price Target to $66.00

Needham & Company LLC has increased its price target for Definium Therapeutics (NASDAQ:DFTX) to $66.00 from $50.00, reiterating a "buy" rating after the company's positive Phase 3 results for its DT120 ODT anxiety treatment. Despite reporting a quarterly loss of $1.44 per share, significantly …

Kratos (KTOS) Stock Is Up, What You Need To Know

Kratos (KTOS) Stock Is Up, What You Need To Know What Happened? Shares of aerospace and defense company Kratos (NASDAQ:KTOS) jumped 2.5% in the afternoon session after the company announced its target systems were successfully used in a joint missile defense exercise with the …

DEFSEC Technologies Inc. Stock Surges 5.62% as Trading Activity Spikes and Market Attention Builds

DEFSEC Technologies Inc. (TSXV:DFSC) saw its shares surge by 5.62% on August 12, 2026, driven by a sudden increase in trading activity and investor attention. The specific catalyst for this sharp rise, common in small-cap technology stocks, has not been independently verified against company …

DeFi Development Corp. Reports Q2 2026 Results, Grows SOL

DeFi Development Corp. (Nasdaq: DFDV) announced its Q2 2026 results, highlighting a 24% year-over-year growth in SOL per share (SPS) to 0.066 and a total of 2,311,523 SOL and equivalents. The company outlined Q3 cost efficiencies, capital structure simplification, and reaffirmed its long-term target …

Definium Therapeutics Says Unprecedented Efficacy From Anxiety Study 'Raises the Bar'

Definium Therapeutics announced highly positive Phase 3 results for its drug DT120 ODT (lysergide) in treating generalized anxiety disorder (GAD), demonstrating statistically significant improvement over placebo. The drug also showed rapid and sustained symptom reduction, a favorable safety profile, and is the second successful …

Wall Street Analysts See a 66.12% Upside in Kratos (KTOS): Can the Stock Really Move This High?

Kratos (KTOS) closed the last trading session at $63.73, gaining 26.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of …

Strong Fundamentals Position Kratos Defense & Security Solutions (KTOS) for Long-Term Upside

Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Discovery Fund". A copy of the letter is available to download here. Baron Discovery Fund appreciated by 19.08% (Institutional Shares) in the quarter, underperforming the Russell 2000 Growth Index, …

Definity Financial’s 1.09% Yield Looks Well Covered as Travelers Integration Expands Earnings Power

Indef Manufacturing Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Definium Therapeutics posts positive Phase 3 Voyage topline: DT120 ODT cuts HAM-A by 5.4 pts vs placebo

Definium Therapeutics announced positive topline data from its Phase 3 Voyage study, demonstrating that DT120 ODT significantly reduced HAM-A scores by 5.4 points compared to placebo at Week 12. The study met its primary and all key secondary endpoints, showing rapid onset of effect …

Kratos Defense Stock Gains 21.4% in 3 Months: Should Investors Buy Now?

Kratos Defense & Security Solutions, Inc.'s KTOS shares have risen 21.4% over the past three months compared with the Zacks Aerospace-Defense Equipment industry's growth of 0.6%. The company maintains a leading position as the U.S. Army's primary supplier of unmanned target drones, with sustained …

Definium Therapeutics shares surge after positive Phase 3 anxiety trial results

Definium Therapeutics (NASDAQ: DFTX) shares jumped 20% in premarket trading after announcing positive topline results from its Phase 3 Voyage study for DT120 ODT in generalized anxiety disorder. The trial met its primary and secondary endpoints, showing a statistically significant improvement in anxiety scores …

Definium Therapeutics (Nasdaq: DFTX) reports positive DT120 GAD Phase 3 data

Definium Therapeutics (Nasdaq: DFTX) announced positive topline results from its Phase 3 Voyage study of DT120 ODT for generalized anxiety disorder (GAD), meeting its primary and all key secondary endpoints with high statistical significance. The study demonstrated rapid, robust, and durable efficacy, with DT120 …

Definium says LSD-based pill reduces anxiety in late-stage study

Definium Therapeutics' experimental LSD-based pill, DT120, significantly reduced anxiety symptoms in a late-stage study, exceeding investor expectations. The single-dose treatment for generalized anxiety disorder (GAD) showed a statistically and clinically meaningful reduction in symptoms, with benefits appearing early and lasting throughout the 12-week study. …

Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder

Definium Therapeutics announced positive topline results from its Phase 3 Voyage study of DT120 ODT for generalized anxiety disorder (GAD), meeting its primary and key secondary efficacy endpoints with statistically significant reductions in HAM-A scores. The study demonstrated rapid, sustained efficacy and a favorable …

Liberty Defense Holdings (SCAN) Stock Drops Nearly 4% on August 11 as Volume Surges — Is Something Bigger Brewing?

Liberty Defense Holdings (TSXV: SCAN) shares dropped nearly 4% on August 11, 2026, with higher-than-usual trading volume, though no specific company announcement caused the movement. The company develops HEXWAVE, an advanced security screening system, and announced a confidential submission for a proposed U.S. IPO …

Definitive Healthcare Corp. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:DH) 2026-08-11

Kratos (KTOS) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026 at 5 p.m. ET CALL PARTICIPANTS Vice President and General Counsel - Marie MendozaPresident and Chief Executive Officer - Eric DeMarcoExecutive Vice President and Chief Financial Officer - Deanna Lund TAKEAWAYS Revenue -- $458.8 …

Kratos Defense & Security Solutions (KTOS) Lands Javelin Seeker Deal After Japan Missile Test Role

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Kratos Defense & Security Solutions (NasdaqGS: KTOS) supplied key systems for Japan's Flight Test Experiment-01 missile defense trial alongside the U.S. Missile Defense …

Definitive Healthcare (DH) Stock Price Slides As Revenue Shrinks And Losses Linger

Kratos Defense And Security Solutions (KTOS) Stock Looks Strong On Returns But Rich On Sales

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Kratos Defense & Security Solutions stock has delivered a very strong 316.5% return over …

KTOS - Aerospace Modernization And Drone Demand Will Fuel Long-Term Upside Momentum

Kratos Defense & Security Solutions (KTOS) is positioned for long-term growth due to aerospace modernization and increased demand for drones, despite a recent slight decrease in implied fair value to $108.62. Analysts view Kratos as a broad defense subsystems and software supplier, not just …

Kratos (KTOS) Stock Looks Fully Priced Despite Strong 3 Year Returns

Kratos Defense & Security Solutions (KTOS) has seen significant returns over the past three years, yet its stock appears expensive according to valuation checks. Trading at a P/S multiple of 7.7x, which is considerably higher than industry averages and its estimated fair value of …

Definium Therapeutics (NASDAQ:DFTX) Trading Down 6.2% - Time to Sell?

Definium Therapeutics (NASDAQ:DFTX) saw its shares drop by 6.2% to $42.34 on Tuesday, with trading volume significantly lower than average. Despite this decline and a quarterly loss exceeding analyst estimates, analysts maintain a "Buy" rating with a $55 price target. Insider selling activity has …

DFTX Stock On Track For Worst Day In 9 Months As Investors Brace For Anxiety Trial Data

Shares of Definium Therapeutics (DFTX) dropped 9% as investors await crucial clinical trial data for the company's psychedelic drug, DT120, a one-time therapy for generalized anxiety disorder. This decline marks its worst day in nine months. The company, which has $1.1 billion in cash, …

H.C. Wainwright Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $70

H.C. Wainwright has reiterated its Buy rating for Definium Therapeutics (DFTX.US) and maintained its target price at $70. This indicates a continued positive outlook from the firm regarding the company's stock performance.

FY2026 Earnings Estimate for KTOS Issued By Noble Financial

Kratos Defense & Security Solutions Stock Surges 42%, With A 8-Day Winning Spree

This article briefly notes that Kratos Defense & Security Solutions stock has surged by 42%. The surge is part of an eight-day winning streak for the company's stock. No further details about the reasons for the surge or financial data are provided in this …

Definitive Healthcare Q2 2026 slides: profit beats amid revenue decline

Definitive Healthcare (NASDAQ:DH) exceeded profitability guidance in Q2 2026 despite a 9% year-over-year revenue decline, driven by strong cost management. The company reported adjusted operating income and adjusted EBITDA above expectations, leading to a 3.08% rise in shares after hours. Definitive Healthcare also raised …

Sapient Capital LLC Sells 262,550 Shares of Kratos Defense & Security Solutions, Inc. $KTOS

Sapient Capital LLC significantly reduced its stake in Kratos Defense & Security Solutions (NASDAQ:KTOS) by 94% in the second quarter, selling 262,550 shares and retaining 16,866 shares. This divestment occurred despite Kratos reporting stronger-than-expected quarterly earnings and revenue. The stock currently holds a "Moderate …

First Trust Advisors LP Decreases Stock Position in COPT Defense Properties $CDP

First Trust Advisors LP significantly reduced its stake in COPT Defense Properties (NYSE:CDP) by 73.4% in the first quarter, selling over 75,000 shares. Despite this, other institutional investors have increased their holdings, and analysts maintain a "Moderate Buy" rating with an average price target …

Top Liberty Defense (DETX) Competitors 2026

This article analyzes Liberty Defense (DETX) by comparing it to five of its competitors: ClearOne (CLRO), Cambium Networks (CMBM), Astrotech (ASTC), SaverOne 2014 (SVRE), and Ostin Technology Group (OST). The comparisons are based on various financial metrics, media sentiment, analyst recommendations, and institutional ownership. …

DeFi Development Corp. Releases June & July 2026 Recap

DeFi Development Corp. (Nasdaq: DFDV) announced its June & July 2026 Business Recap, introducing the SOL Boost Framework to provide leveraged Solana (SOL) exposure and an interactive SOL Boost Calculator for investors. The recap also highlighted organizational streamlining, validator expansion, the transition of DisclaimerCoin …

Definitive Healthcare targets $220M-$222M 2026 revenue while planning Turbo general availability before year-end

Earnings Call Insights: Definitive Healthcare (DH) Q2 2026 MANAGEMENT VIEW * "Total revenue was $55.2 million, down 9% year-over-year. Adjusted EBITDA was $14.6 million, representing a margin of 26%" (CEO Kevin Coop). * "Our diversified and provider businesses continue to be further along in …

Definitive Healthcare earnings beat by $0.01, revenue fell short of estimates